Nyxoah Announces Upcoming Investor Events
Nyxoah (NASDAQ: NYXH), a medical technology company focused on Obstructive Sleep Apnea (OSA) treatment, has announced its participation in four major healthcare investor conferences in September 2025.
The company will attend the Wells Fargo Healthcare Conference in Boston (Sept 3), Cantor Global Healthcare Conference in New York (Sept 4, 11:30-12:00 pm ET), Morgan Stanley Global Healthcare Conference in New York (Sept 9, 5:35-6:10 pm ET), and Baird's Global Healthcare Conference in New York (Sept 10). Live webcasts will be available on Nyxoah's Investor Relations website, and the company will conduct one-on-one meetings with institutional investors.
Nyxoah (NASDAQ: NYXH), società di tecnologia medica specializzata nel trattamento dell'apnea ostruttiva del sonno (OSA), ha annunciato la sua partecipazione a quattro importanti conferenze per investitori nel settore sanitario a settembre 2025.
L'azienda sarà presente al Wells Fargo Healthcare Conference a Boston (3 set), al Cantor Global Healthcare Conference a New York (4 set, 11:30-12:00 ET), al Morgan Stanley Global Healthcare Conference a New York (9 set, 17:35-18:10 ET) e al Baird's Global Healthcare Conference a New York (10 set). I webcast in diretta saranno disponibili sul sito Investor Relations di Nyxoah e la società terrà incontri one-to-one con investitori istituzionali.
Nyxoah (NASDAQ: NYXH), una empresa de tecnología médica centrada en el tratamiento de la apnea obstructiva del sueño (AOS), ha anunciado su participación en cuatro importantes conferencias para inversores del sector sanitario en septiembre de 2025.
La compañía asistirá al Wells Fargo Healthcare Conference en Boston (3 de sept), al Cantor Global Healthcare Conference en Nueva York (4 de sept, 11:30-12:00 ET), al Morgan Stanley Global Healthcare Conference en Nueva York (9 de sept, 17:35-18:10 ET) y al Baird's Global Healthcare Conference en Nueva York (10 de sept). Habrá retransmisiones en vivo disponibles en la web de Investor Relations de Nyxoah, y la compañía celebrará reuniones one-to-one con inversores institucionales.
Nyxoah (NASDAQ: NYXH)는 폐쇄성 수면무호흡증(OSA) 치료에 주력하는 의료기술 기업으로, 2025년 9월 주요 헬스케어 투자자 컨퍼런스 네 곳에 참가한다고 발표했습니다.
회사는 Wells Fargo Healthcare Conference(보스턴, 9월 3일), Cantor Global Healthcare Conference(뉴욕, 9월 4일, 오후 11:30-12:00 ET), Morgan Stanley Global Healthcare Conference(뉴욕, 9월 9일, 오후 5:35-6:10 ET), Baird's Global Healthcare Conference(뉴욕, 9월 10일)에 참석합니다. 실시간 웹캐스트는 Nyxoah 투자자 관계 웹사이트에서 제공되며, 기관 투자자와의 일대일 미팅도 진행할 예정입니다.
Nyxoah (NASDAQ: NYXH), société de technologie médicale spécialisée dans le traitement de l'apnée obstructive du sommeil (AOS), a annoncé sa participation à quatre grandes conférences investisseurs du secteur de la santé en septembre 2025.
La société assistera à la Wells Fargo Healthcare Conference à Boston (3 sept.), à la Cantor Global Healthcare Conference à New York (4 sept., 11h30-12h00 ET), à la Morgan Stanley Global Healthcare Conference à New York (9 sept., 17h35-18h10 ET) et à la Baird's Global Healthcare Conference à New York (10 sept.). Des webcasts en direct seront disponibles sur le site Investor Relations de Nyxoah, et la société tiendra des réunions individuelles avec des investisseurs institutionnels.
Nyxoah (NASDAQ: NYXH), ein Medizintechnikunternehmen mit Fokus auf die Behandlung der obstruktiven Schlafapnoe (OSA), hat seine Teilnahme an vier großen Healthcare-Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird an der Wells Fargo Healthcare Conference in Boston (3. Sept.), der Cantor Global Healthcare Conference in New York (4. Sept., 11:30–12:00 ET), der Morgan Stanley Global Healthcare Conference in New York (9. Sept., 17:35–18:10 ET) und der Baird's Global Healthcare Conference in New York (10. Sept.) teilnehmen. Live-Webcasts sind auf der Investor-Relations-Website von Nyxoah verfügbar, und das Unternehmen wird Einzelgespräche mit institutionellen Investoren führen.
- None.
- None.
Nyxoah Announces Upcoming Investor Events
Mont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the following events during September:
2025 Wells Fargo Healthcare Conference
September 3rd – Boston, MA
Cantor Global Healthcare Conference 2025
September 4th – New York, NY
Fireside Chat: 11:30-12:00 pm ET
Webcast: Cantor Fireside Chat Webcast
Morgan Stanley 23rd Annual Global Healthcare Conference
September 9th – New York, NY
Presentation Time: 5:35-6:10 pm ET
Webcast: : Morgan Stanley Fireside Chat Webcast
Baird's 2025 Global Healthcare Conference
September 10th – New York, NY
A live webcast of the events can be accessed by visiting Nyxoah’s Investor Relations website and will be available for replay following the events. The Company will also be available for 1x1 meetings with institutional investors attending the events.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and U.S. FDA approval of a Premarket Approval application.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
FORWARD-LOOKING STATEMENTS
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
John Landry, CFO
IR@nyxoah.com
For Media
In United States
FINN Partners – Alyssa Paldo
alyssa.paldo@finnpartners.com
In International/Germany
MC Services – Anne Hennecke
anne.hennecke@mc-services.eu
In Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be
Attachment
FAQ
When is Nyxoah (NYXH) presenting at the Morgan Stanley Healthcare Conference 2025?
Where can I watch Nyxoah's (NYXH) healthcare conference presentations?
What investor conferences is Nyxoah (NYXH) attending in September 2025?
What time is Nyxoah's (NYXH) presentation at the Cantor Global Healthcare Conference?
